Comprehensive imaging of ischemic stroke with multisection CT.

Radiographics

Division of Neuroradiology, Department of Neurosurgery, University of Erlangen-Nuremberg, Schwabachanlage 6, D-91054 Erlangen, Germany.

Published: October 2003

Computed tomography (CT) is an established tool for the diagnosis of ischemic or hemorrhagic stroke. Nonenhanced CT can help exclude hemorrhage and detect "early signs" of infarction but cannot reliably demonstrate irreversibly damaged brain tissue in the hyperacute stage of ischemic stroke. Further evaluation of patients with ischemic stroke should include differentiation between reversible and irreversible brain damage, which is essential for choosing an appropriate therapy. Perfusion CT provides information about brain perfusion, which permits differentiation of irreversibly damaged brain tissue from reversibly impaired "tissue at risk." CT angiography can help detect stenosis or occlusion of extra- and intracranial arteries. Multisection CT allows the combined use of all three imaging modalities-nonenhanced CT, perfusion CT, and CT angiography-to rapidly obtain comprehensive information regarding the extent of ischemic damage in acute stroke patients. Specific patterns of findings are typically seen in ischemic stroke and can be analyzed more accurately with the combined use of multisection CT and MR imaging. Nevertheless, prospective studies involving a large number of patients will be needed to ascertain the treatment of choice for patients with each of these patterns of findings.

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.233025036DOI Listing

Publication Analysis

Top Keywords

ischemic stroke
16
irreversibly damaged
8
damaged brain
8
brain tissue
8
patterns findings
8
ischemic
6
stroke
6
comprehensive imaging
4
imaging ischemic
4
stroke multisection
4

Similar Publications

Dysregulation of long non-coding RNAs (lncRNAs) is implicated in the pathophysiology of ischemic stroke (IS). However, the molecular mechanism of the lncRNA SERPINB9P1 in IS remains unclear. Our study aimed to explore the role and molecular mechanism of the lncRNA SERPINB9P1 in IS.

View Article and Find Full Text PDF

Stroke is the second-leading global cause of death. The damage attributed to the immune storm triggered by ischemia-reperfusion injury (IRI) post-stroke is substantial. However, data on the transcriptomic dynamics of pyroptosis in IRI are limited.

View Article and Find Full Text PDF

Cardiovascular Outcomes With Antidiabetic Drugs in People With Type 2 Diabetes and a Prior Stroke.

Mayo Clin Proc

January 2025

Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea; Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea. Electronic address:

Objective: To assess the comparative effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i), thiazolidinediones (TZD), and dipeptidyl peptidase-4 inhibitors (DPP-4i) for the cardiorenal outcomes and mortality in individuals with type 2 diabetes and a prior stroke.

Patients And Methods: Using the Korean National Health Insurance Service database from 2014 to 2021, a new-user cohort was established through propensity score matching for SGLT2i, TZD, and DPP-4i. The primary outcomes were major adverse cardiovascular events (MACE), comprising myocardial infarction, ischemic stroke, and cardiovascular death.

View Article and Find Full Text PDF

Objective: This study aimed to investigate the relationship between mortality and the frontal QRS-T angle (FQRS-TA), obtained by calculating the absolute difference between the QRS and T waves electrocardiographically (ECG), in patients diagnosed with ischemic stroke (IS).

Methods: This research is a retrospective and cross-sectional study. The diagnosis of IS was confirmed through brain imaging and physical examination.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!